HERTFORDSHIRE, England and PITTSBURGH, Aug. 5, 2016 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has completed the settlement of its recommended public offer to the shareholders of Meda Aktiebolag (publ.) to tender all their shares in Meda to Mylan (the “Offer”). As previously announced, the Offer was accepted by shareholders holding […]
SUNRISE, Florida, July 22, 2016 – MDLIVE, the nation’s leader in the rapidly growing virtual health market, is pleased to announce the appointment of Dr. Sanjay Patil as Executive Vice President and General Manager of Health Systems Strategy and Transformation. In his new role, Dr. Patil will lead an experienced team of healthcare and technology […]
SUNRISE, Florida, July 15, 2016 – MDLIVE, the nation’s leader in the rapidly growing virtual health market, today announced that Dr. Sylvan Waller has been appointed SVP and Chief Medical Officer of MDLIVE, Inc. effective immediately. Dr. Waller is a board-certified emergency medicine physician with more than 16 years of medical, financial management, business operations […]
Phase 3 Data Published in the Journal of the American Academy of Dermatology July 13, 2016 – Pfizer Inc. (NYSE:PFE) announced today the publication of findings from two pivotal Phase 3 studies of investigational crisaborole topical ointment 2% (formerly AN2728) in the online issue of the Journal of the American Academy of Dermatology. “Atopic dermatitis, […]
Prevnar 13 is the only pneumococcal vaccine approved in the U.S. for patients 6 weeks through adulthood July 12, 2016 – Pfizer Inc. (NYSE:PFE) today announced that Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received U.S. Food and Drug Administration (FDA) approval for an expanded age indication to include adults 18 through 49 […]
S-TRAC is the First RCC Trial of a Tyrosine Kinase Inhibitor to Prolong Disease-Free Survival in the Adjuvant Setting July 8, 2016 – Pfizer Inc. (NYSE:PFE) today announced that the S-TRAC clinical trial (Sunitinib Trial in Adjuvant RenalCancer), a Phase 3 study of SUTENT versus placebo in the adjuvant setting, met its primary endpoint of improving […]
First Phase III trial evaluating the addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women July 6, 2016 – Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced the initiation of a Phase III study, JAVELIN Ovarian […]
Companies working alongside providers to develop solutions to serious public health needs KENILWORTH, N.J. and CHARLOTTE, N.C. June 30, 2016 — Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, have agreed to collaborate on the co-development of solutions to help improve population health. […]
Collaboration Combines Merck’s Leadership in Immuno-Oncology with Moderna’s Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities KENILWORTH, N.J. & CAMBRIDGE, Mass. June 29, 2016 — (BUSINESS WIRE) — Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to […]
Collaboration Combines Merck’s Leadership in Immuno-Oncology with Moderna’s Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities KENILWORTH, N.J. & CAMBRIDGE, Mass. June 29, 2016 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize […]